C1 inhibitor (蛋白 | 抗体 | cDNA 克隆 | ELISA 试剂盒)

All C1 inhibitor reagents are produced in house and quality controlled, including 5 C1 inhibitor Antibody, 2 C1 inhibitor ELISA, 52 C1 inhibitor Gene, 1 C1 inhibitor IP Kit, 2 C1 inhibitor Lysate, 2 C1 inhibitor Protein, 1 C1 inhibitor qPCR. All C1 inhibitor reagents are ready to use.

C1 inhibitor Protein (2)

C1 inhibitor Antibody (5)

C1 inhibitor ELISA 试剂盒(即用型)& ELISA 抗体对套装(非即用型)(2)

C1 inhibitor cDNA Clone (52)

NM_000062.2

克隆载体 cDNA 产品

In lentiviral vector

NM_009776.3

克隆载体 cDNA 产品

In lentiviral vector

XM_006234447.1

克隆载体 cDNA 产品

In lentiviral vector

XM_004777588.1

克隆载体 cDNA 产品

In lentiviral vector

C1 inhibitor qPCR Primer (1)

C1 inhibitor Lysate (2)

更多受客户欢迎的产品

C1 inhibitor 相关研究领域

C1 inhibitor 分子背景

Plasma protease C1 inhibitor, also known as C1-inhibiting factor, C1-INH, C1 esterase inhibitor, SERPING1 and C1IN, is a serine proteinase inhibitor (serpin) that regulates activation of both the complement and contact systems. By its C-terminal part (serpin domain), characterized by three beta-sheets and an exposed mobile reactive loop, C1-INH binds, and blocks the activity of its target proteases. The N-terminal end (nonserpin domain) confers to C1-INH the capacity to bind lipopolysaccharides and E-selectin. Owing to this moiety, C1-INH intervenes in regulation of the inflammatory reaction. The heterozygous deficiency of C1-INH results in hereditary angioedema (HAE). Owing to its ability to modulate the contact and complement systems and the convincing safety profile, plasma-derived C1 inhibitor is an attractive therapeutic protein to treat inflammatory diseases other than HAE. Deficiency of C1 inhibitor results in hereditary angioedema, which is characterized by recurrent episodes of localized angioedema of the skin, gastrointestinal mucosa or upper respiratory mucosa. C1 inhibitor may prove useful in a variety of other diseases including septic shock, reperfusion injury, hyperacute transplant rejection, traumatic and hemorrhagic shock, and the increased vascular permeability associated with thermal injury, interleukin-2 therapy and cardiopulmonary bypass.

C1 inhibitor 参考文献

  • Davis AE 3rd. et al. (2004) Biological effects of C1 inhibitor. Drug News Perspect. 17(7): 439-46.
  • Cicardi M, et al. (2005) C1 inhibitor: molecular and clinical aspects. Springer Semin Immunopathol. 27(3): 286-98.
  • Wouters D, et al. (2008) C1 inhibitor: just a serine protease inhibitor? New and old considerations on therapeutic applications of C1 inhibitor. Expert Opin Biol Ther. 8(8): 1225-40.
  • Cugno M, et al. (2009) C1-inhibitor deficiency and angioedema: molecular mechanisms and clinical progress. Trends Mol Med. 15(2): 69-78.